Log in

Relevant bibliographies by topics / Amyloid-PET / Journal articles

To see the other types of publications on this topic, follow the link: Amyloid-PET.

Journal articles on the topic 'Amyloid-PET'

Author: Grafiati

Published: 2 June 2025

Last updated: 31 July 2025

Create a spot-on reference in APA, MLA, Chicago, Harvard, and other styles

Select a source type:

Consult the top 50 journal articles for your research on the topic 'Amyloid-PET.'

Next to every source in the list of references, there is an 'Add to bibliography' button. Press on it, and we will generate automatically the bibliographic reference to the chosen work in the citation style you need: APA, MLA, Harvard, Chicago, Vancouver, etc.

You can also download the full text of the academic publication as pdf and read online its abstract whenever available in the metadata.

Browse journal articles on a wide variety of disciplines and organise your bibliography correctly.

1

Rhodius-Meester, Hanneke F. M., Ingrid S. van Maurik, Lyduine E. Collij, et al. "Computerized decision support is an effective approach to select memory clinic patients for amyloid-PET." PLOS ONE 19, no. 5 (2024): e0303111. http://dx.doi.org/10.1371/journal.pone.0303111.

Full text

Abstract:

Background The use of amyloid-PET in dementia workup is upcoming. At the same time, amyloid-PET is costly and limitedly available. While the appropriate use criteria (AUC) aim for optimal use of amyloid-PET, their limited sensitivity hinders the translation to clinical practice. Therefore, there is a need for tools that guide selection of patients for whom amyloid-PET has the most clinical utility. We aimed to develop a computerized decision support approach to select patients for amyloid-PET. Methods We included 286 subjects (135 controls, 108 Alzheimer’s disease dementia, 33 frontotemporal l

APA, Harvard, Vancouver, ISO, and other styles

2

Tan, Meng-Shan, Yu-Xiang Yang, Hui-Fu Wang, et al. "PET Amyloid and Tau Status Are Differently Affected by Patient Features." Journal of Alzheimer's Disease 78, no. 3 (2020): 1129–36. http://dx.doi.org/10.3233/jad-200124.

Full text

Abstract:

Background: Amyloid-β (Aβ) plaques and tau neurofibrillary tangles are two neuropathological hallmarks of Alzheimer’s disease (AD), which both can be visualized in vivo using PET radiotracers, opening new opportunities to study disease mechanisms. Objective: Our study investigated 11 non-PET factors in 5 categories (including demographic, clinical, genetic, MRI, and cerebrospinal fluid (CSF) features) possibly affecting PET amyloid and tau status to explore the relationships between amyloid and tau pathology, and whether these features had a different association with amyloid and tau status. M

APA, Harvard, Vancouver, ISO, and other styles

3

Frey, K. A., and R. A. Koeppe. "PET Amyloid Analyses." Journal of Nuclear Medicine 57, no. 8 (2016): 1168–69. http://dx.doi.org/10.2967/jnumed.116.173989.

Full text

APA, Harvard, Vancouver, ISO, and other styles

4

Chételat, Gaël, and Melissa E. Murray. "Amyloid PET scan." Neurology 89, no. 20 (2017): 2029–30. http://dx.doi.org/10.1212/wnl.0000000000004678.

Full text

APA, Harvard, Vancouver, ISO, and other styles

5

Kepe, Vladimir. "Amyloid PET Imaging." PET Clinics 8, no. 4 (2013): 431–45. http://dx.doi.org/10.1016/j.cpet.2013.08.002.

Full text

APA, Harvard, Vancouver, ISO, and other styles

6

Høilund-Carlsen, Poul F., Abass Alavi, and Jorge R. Barrio. "PET/CT/MRI in Clinical Trials of Alzheimer’s Disease." Journal of Alzheimer's Disease 101, s1 (2024): S579—S601. http://dx.doi.org/10.3233/jad-240206.

Full text

Abstract:

With the advent of PET imaging in 1976, 2-deoxy-2-[18F]fluoro-D-glucose (FDG)-PET became the preferred method for in vivo investigation of cerebral processes, including regional hypometabolism in Alzheimer’s disease. With the emergence of amyloid-PET tracers, [11C]Pittsburgh Compound-B in 2004 and later [18F]florbetapir, [18F]florbetaben, and [18F]flumetamol, amyloid-PET has replaced FDG-PET in Alzheimer’s disease anti-amyloid clinical trial treatments to ensure “amyloid positivity” as an entry criterion, and to measure treatment-related decline in cerebral amyloid deposits. MRI has been used

APA, Harvard, Vancouver, ISO, and other styles

7

Raposo, Nicolas, and Joshua A. Sonnen. "Amyloid-PET in cerebral amyloid angiopathy." Neurology 89, no. 14 (2017): 1437–38. http://dx.doi.org/10.1212/wnl.0000000000004548.

Full text

APA, Harvard, Vancouver, ISO, and other styles

8

Perani, Daniela. "FDG-PET and amyloid-PET imaging." Current Opinion in Neurology 27, no. 4 (2014): 405–13. http://dx.doi.org/10.1097/wco.0000000000000109.

Full text

APA, Harvard, Vancouver, ISO, and other styles

9

Sarkis, Rani A., Seth A. Gale, Hyun-Sik Yang, et al. "Utility of Amyloid Positron Emission Tomography Imaging in Older Adults With Epilepsy and Cognitive Decline." American Journal of Alzheimer's Disease & Other Dementias® 38 (January 2023): 153331752311600. http://dx.doi.org/10.1177/15333175231160005.

Full text

Abstract:

In older adults with cognitive decline and epilepsy, diagnosing the etiology of cognitive decline is challenging. We identified 6 subjects enrolled in the Imaging Dementia-Evidence of Amyloid Imaging Scanning (IDEAS) study and nonlesional epilepsy. Three cognitive neurologists reviewed each case to determine the likelihood of underlying Alzheimer’s disease (AD) pathology. Their impressions were compared to amyloid PET findings. In 3 cases the impression was concordant with PET findings. In 2 cases “possibly suggestive,” the PET reduced diagnostic uncertainty, with 1 having a PET without elevat

APA, Harvard, Vancouver, ISO, and other styles

10

Isadora, Lopes Alves, E. Collij Lyduine, Altomare Daniele, et al. "Quantitative amyloid PET in Alzheimer's disease: the AMYPAD prognostic and natural history study." Alzheimer's & Dementia 16, no. 5 (2020): 750–58. https://doi.org/10.1002/alz.12069.

Full text

Abstract:

<strong>Abstract</strong> Introduction: The Amyloid Imaging to Prevent Alzheimer's Disease (AMYPAD) Prognostic and Natural History Study (PNHS) aims at understanding the role of amyloid imaging in the earliest stages of Alzheimer's disease (AD). AMYPAD PNHS adds (semi-)quantitative amyloid PET imaging to several European parent cohorts (PCs) to predict AD-related progression as well as address methodological challenges in amyloid PET. Methods: AMYPAD PNHS is an open-label, prospective, multi-center, cohort study recruiting from multiple PCs. Around 2000 participants will unde

APA, Harvard, Vancouver, ISO, and other styles

11

Charidimou, Andreas, Karim Farid, and Jean-Claude Baron. "Amyloid-PET in sporadic cerebral amyloid angiopathy." Neurology 89, no. 14 (2017): 1490–98. http://dx.doi.org/10.1212/wnl.0000000000004539.

Full text

Abstract:

Objective:To perform a meta-analysis synthesizing evidence of the value and accuracy of amyloid-PET in diagnosing patients with sporadic cerebral amyloid angiopathy (CAA).Methods:In a PubMed systematic literature search, we identified all case-control studies with extractable data relevant for the sensitivity and specificity of amyloid-PET positivity in symptomatic patients with CAA (cases) vs healthy participants or patients with spontaneous deep intracerebral hemorrhage (ICH) (control groups). Using a hierarchical (multilevel) logistic regression model, we calculated pooled diagnostic test a

APA, Harvard, Vancouver, ISO, and other styles

12

Nordberg, Agneta. "The use of amyloid imaging in clinical praxis: a critical review." Clinical and Translational Imaging 3, no. 1 (2015): 7–11. https://doi.org/10.1007/s40336-015-0100-8.

Full text

Abstract:

Recent development in molecular imaging enables measurement of fibrillar amyloid plaque in Alzheimer (AD) brain using positron emission tomography (PET). Three tracers (florbetapir, flutemetamol, florbetaben) have been approved by FDA and EMA for use in clinical assessment of memory impairment to exclude AD. The use of amyloid PET imaging is considered to be appropriate in patients with persistent and progressive unexplained mild cognitive impairment (MCI), in patients with established dementia with atypical clinical course or aetiology and in young patients with atypical-onset dementia. The f

APA, Harvard, Vancouver, ISO, and other styles

13

Charidimou, Andreas, Karim Farid, Hsin-Hsi Tsai, Li-Kai Tsai, Rouh-Fang Yen, and Jean-Claude Baron. "Amyloid-PET burden and regional distribution in cerebral amyloid angiopathy: a systematic review and meta-analysis of biomarker performance." Journal of Neurology, Neurosurgery & Psychiatry 89, no. 4 (2017): 410–17. http://dx.doi.org/10.1136/jnnp-2017-316851.

Full text

Abstract:

IntroductionWe performed a meta-analysis to synthesise current evidence on amyloid-positron emission tomography (PET) burden and presumed preferential occipital distribution in sporadic cerebral amyloid angiopathy (CAA).MethodsIn a PubMed systematic search, we identified case–control studies with extractable data on global and occipital-to-global amyloid-PET uptake in symptomatic patients with CAA (per Boston criteria) versus control groups (healthy participants or patients with non-CAA deep intracerebral haemorrhage) and patients with Alzheimer’s disease. To circumvent PET studies’ methodolog

APA, Harvard, Vancouver, ISO, and other styles

14

Kolanko, Magdalena A., Zarni Win, Flavia Loreto, et al. "Amyloid PET imaging in clinical practice." Practical Neurology 20, no. 6 (2020): 451–62. http://dx.doi.org/10.1136/practneurol-2019-002468.

Full text

Abstract:

Amyloid positron emission tomography (PET) imaging enables in vivo detection of brain Aβ deposition, one of the neuropathological hallmarks of Alzheimer’s disease. There is increasing evidence to support its clinical utility, with major studies showing that amyloid PET imaging improves diagnostic accuracy, increases diagnostic certainty and results in therapeutic changes. The Amyloid Imaging Taskforce has developed appropriate use criteria to guide clinicians by predefining certain scenarios where amyloid PET would be justified. This review provides a practical guide on how and when to use amy

APA, Harvard, Vancouver, ISO, and other styles

15

Carrera-Muñoz, Ismael, Lucía Triguero-Cueva, Juan C. Romero-Fábrega, et al. "PET-Amyloid After Inconclusive Cerebrospinal Fluid Biomarkers in Clinical Practice. Is it Necessary to Duplicate Procedures?" Current Alzheimer Research 17, no. 8 (2020): 698–708. http://dx.doi.org/10.2174/1567205017666201109092637.

Full text

Abstract:

Introduction: In the absence of a gold standard for in vivo Alzheimer disease (AD) diagnosis, AD biomarkers such as cerebrospinal fluid biomarkers (CSF-B) and PET-Amyloid are considered diagnostically useful in clinical practice guidelines and have consensual appropriate use criteria (AUC). However, little evidence has been published on their utilization in the clinical setting or on approaches to mismatched results. The objective of this work was to evaluate the use of AD biomarkers in clinical practice, focusing on the implementation of PET-Amyloid in cases of inconclusive CSF-B. Methods: Th

APA, Harvard, Vancouver, ISO, and other styles

16

Enrico, Fantoni, Collij Lyduine, Lopes Alves Isadora, Buckley Christopher, and Farrar Gill. "The spatial-temporal ordering of amyloid pathology and opportunities for PET imaging." JOURNAL OF NUCLEAR MEDICINE 61, no. 2 (2019): 166–71. https://doi.org/10.2967/jnumed.119.235879.

Full text

Abstract:

<strong>Abstract: </strong> While clinical routine focuses on dichotomous and visual interpretation of amyloid PET, in a research setting, regional image assessment may yield additional opportunities. Understanding the regional-temporal evolution of amyloid pathology may enable the earlier identification of subjects who are in the Alzheimer’s Disease pathological continuum, as well as a more fine-grained assessment of pathology beyond traditional dichotomous measures. This review summarises the current research in the detection of regional amyloid deposition patterns and its potenti

APA, Harvard, Vancouver, ISO, and other styles

17

Zedde, Marialuisa, Fabrizio Piazza, and Rosario Pascarella. "Positron Emission Tomography in Cerebral Amyloid Angiopathy: A Scoping Review." Applied Sciences 15, no. 7 (2025): 3973. https://doi.org/10.3390/app15073973.

Full text

Abstract:

Background/Objectives: Cerebral amyloid angiopathy (CAA) is one of the most prevalent small vessel diseases (SVDs). Its diagnostic criteria rely mainly on neuroimaging markers, in particular using Magnetic Resonance Imaging (MRI), as pathology-based diagnoses are only occasionally available. Amyloid PET is frequently used to assess parenchymal amyloid deposition in Alzheimer’s disease (AD), but amyloid tracers are not specific to vascular and parenchymal amyloids. The aim of this scoping review is to assess the usefulness of amyloid PET imaging in CAA. Methods: A systematic literature search w

APA, Harvard, Vancouver, ISO, and other styles

18

Lombardi, Gemma, Valentina Berti, Andrea Ginestroni, Benedetta Nacmias, and Sandro Sorbi. "The Association Between Positive Amyloid-PET and Cognitive Decline Is Not Always Supportive of Alzheimer’s Disease: Suggestions from a Case Report." Journal of Alzheimer's Disease Reports 8, no. 1 (2024): 281–88. http://dx.doi.org/10.3233/adr-230183.

Full text

Abstract:

Amyloid-β deposition is the pathological hallmark of both cerebral amyloid angiopathy and Alzheimer’s disease dementia, clinical conditions that can share cognitive decline and positive Amyloid-PET scan. A case is reported involving an 82-year-old Italian female who presented initially a memory deficit, later transient focal neurologic episodes, and finally two symptomatic lobar intracerebral hemorrhages. In light of these events, MRI and PET imaging findings, acquired before cerebral hemorrhages, are reconsidered and discussed, highlighting the utility of Amyloid-PET in supporting an in vivo

APA, Harvard, Vancouver, ISO, and other styles

19

Siriprapa, Tossaporn, Tanyaluck Thientunyakit, and Juri Gelovani. "Amyloid PET Radiopharmaceuticals and Imaging for Clinical and Research Applications in Thailand." Siriraj Medical Journal 75, no. 9 (2023): 688–98. http://dx.doi.org/10.33192/smj.v75i9.263161.

Full text

Abstract:

In the past two decades, the research community has focused on defining reliable molecular biomarkers for the early diagnosis of Alzheimer's disease (AD). Several PET radiopharmaceuticals have been developed and gained regulatory approval for the non-invasive detection of Aβ amyloid deposits in the brain. Nowadays, there are several PET imaging tracers available in Thailand for amyloid imaging including [11C]PiB, [18F]Florbetapir, and [18F]Florbetaben. This review provides a summary of commonly used amyloid PET radiopharmaceuticals, focusing on the available radiopharmaceuticals in Thailand an

APA, Harvard, Vancouver, ISO, and other styles

20

Ho, Seong Hee, та Dong-Won Yang. "Risk Factors Predicting Amyloid PET Positivity in Patients with Mild Cognitive Impairment and Apolipoprotein E ɛ3/ɛ3 Genotypes". Journal of Alzheimer's Disease 77, № 3 (2020): 1017–24. http://dx.doi.org/10.3233/jad-200439.

Full text

Abstract:

Background: The apolipoprotein E (APOE) ɛ4 allele is a well-known risk factor for AD and is associated with higher amyloid deposition and earlier dementia onset. However, the relationship between amyloid pathology and the most common APOE allele, ɛ3, has not been well studied. Objective: In this study, we aimed to identify the risk factors predicting amyloid PET positivity in patients with mild cognitive impairment (MCI) and APOE ɛ3/ɛ3 genotypes. Methods: We retrospectively reviewed the medical records of MCI patients with APOE ɛ3/ɛ3 genotypes who underwent amyloid PET scanning. Demographics,

APA, Harvard, Vancouver, ISO, and other styles

21

Kim, Yejin, Paul Rosenberg, and Esther Oh. "A Review of Diagnostic Impact of Amyloid Positron Emission Tomography Imaging in Clinical Practice." Dementia and Geriatric Cognitive Disorders 46, no. 3-4 (2018): 154–67. http://dx.doi.org/10.1159/000492151.

Full text

Abstract:

Background: Molecular imaging of brain amyloid for the diagnosis of Alzheimer’s disease (AD) using positron emission tomography (PET) has been approved for use in clinical practice by the Food and Drug Administration (FDA) since 2012. However, the clinical utility and diagnostic impact of amyloid PET imaging remain controversial. We conducted a review of the recent studies investigating clinical utility of amyloid PET imaging with focus on changes in diagnosis, diagnostic confidence, and patient management. Summary: A total of 16 studies were included in the final analysis. Overall rate of cha

APA, Harvard, Vancouver, ISO, and other styles

22

Ennis, Gilda E., Rebecca E. Langhough, Karly Alex Cody, et al. "Cross‐sectional associations between amyloid and tau PET and cognitive performance in Black adults without dementia: Preliminary results from the African Americans Fighting Alzheimer’s in Mid‐life study." Alzheimer's & Dementia 19, S24 (2023). http://dx.doi.org/10.1002/alz.083062.

Full text

Abstract:

AbstractBackgroundFew studies have examined amyloid and tau and cognitive performance in samples solely comprised of African American (AA) adults. The African Americans Fighting Alzheimer’s in Mid‐life (AA‐FAIM) study (n = 293 active AA participants) is currently collecting amyloid and tau positron emission tomography (PET) scans. Preliminary cross‐sectional associations between amyloid and tau PET and cognitive performance are presented here.MethodN = 55 adults without dementia had amyloid and/or tau PET (n = 48 had amyloid PET; n = 47 had tau PET; n = 40 had both scans). 11C‐Pittsburgh Compo

APA, Harvard, Vancouver, ISO, and other styles

23

Burnham, Samantha C., Laura Harper, Tricia Locascio, Holly E. McPherson, Michael Pontecorvo, and Jian Wang. "Evaluating the interchangeability of blood‐based biomarkers and amyloid‐PET for identifying patients with Alzheimer’s pathology." Alzheimer's & Dementia 20, S2 (2024). https://doi.org/10.1002/alz.091465.

Full text

Abstract:

AbstractBackgroundPresence of amyloid pathology is used to identify patients who would benefit from novel amyloid‐targeting therapies for Alzheimer’s disease (AD). Whilst PET tracers are considered the gold standard for establishing the presence of amyloid pathology, they are costly and not widely accessible. Blood‐based biomarkers, if interchangeable with PET, could help negate such an inequitable barrier to treatment. This study assesses the agreement and interchangeability between blood‐based biomarkers and amyloid‐PET.MethodBioHermes participants with MCI or AD‐dementia and available amylo

APA, Harvard, Vancouver, ISO, and other styles

24

Park, Kee Hyung, YongSoo Shim, Seong Hye Choi, Young Chul Youn, Dong Won Yang, and SangYun Kim. "Reconsideration of appropriate use criteria for amyloid PET based on real‐world experiences." Alzheimer's & Dementia 19, S16 (2023). http://dx.doi.org/10.1002/alz.079430.

Full text

Abstract:

AbstractBackgroundAmyloid PET can detect brain abnormality at very early stages of AD. However, deciding which patients should undergo amyloid PET requires careful consideration, because of its expense and the lack of treatment options. Until now, 2013 recommendations for appropriate use of amyloid PET, by Amyloid Imaging Taskforce, have been used widely. However, anti‐amyloid treatment is becoming available, so it is an appropriate time to reconsider the optimal criteria for amyloid PET use. In Korea, amyloid PET is widely used in clinical practice due to its low cost and easy accessibility.

APA, Harvard, Vancouver, ISO, and other styles

25

Yang, Jhih-Yong, Yung-Tsai Chu, Hsin-Hsi Tsai, and Jiann-Shing Jeng. "Amyloid and tau PET in cerebral amyloid angiopathy-related inflammation two case reports and literature review." Frontiers in Neurology 14 (April 28, 2023). http://dx.doi.org/10.3389/fneur.2023.1153305.

Full text

Abstract:

BackgroundCerebral amyloid angiopathy-related inflammation (CAA-ri) is a clinical syndrome characterized by MRI findings of amyloid-related imaging abnormalities-edema (ARIA-E) suggestive of autoimmune and inflammatory reaction and hemorrhagic evidence of cerebral amyloid angiopathy. The longitudinal variation of amyloid PET and its imaging association with CAA-ri are undetermined. Moreover, tau PET in CAA-ri has been rarely investigated.MethodWe retrospectively described two cases of CAA-ri. We provided the temporal change of amyloid and tau PET in the first case, and the cross-sectional find

APA, Harvard, Vancouver, ISO, and other styles

26

Rubinski, Anna, Nicolai Franzmeier, Julia Neitzel, and Michael Ewers. "FDG-PET hypermetabolism is associated with higher tau-PET in mild cognitive impairment at low amyloid-PET levels." Alzheimer's Research & Therapy 12, no. 1 (2020). http://dx.doi.org/10.1186/s13195-020-00702-6.

Full text

Abstract:

Abstract Background FDG-PET hypermetabolism can be observed in mild cognitive impairment (MCI), but the link to primary pathologies of Alzheimer’s diseases (AD) including amyloid and tau is unclear. Methods Using voxel-based regression, we assessed local interactions between amyloid- and tau-PET on spatially matched FDG-PET in 72 MCI patients. Control groups included cerebrospinal fluid biomarker characterized cognitively normal (CN, n = 70) and AD dementia subjects (n = 95). Results In MCI, significant amyloid-PET by tau-PET interactions were found in frontal, lateral temporal, and posterior

APA, Harvard, Vancouver, ISO, and other styles

27

An, Binchong, Danni Li, and Lu Men. "Discordance between CSF and PET biomarkers of amyloid pathology are associated with distinct pathophysiologic process in early stages of Alzheimer’s disease." Alzheimer's & Dementia 20, S2 (2024). https://doi.org/10.1002/alz.089461.

Full text

Abstract:

AbstractBackgroundAlzheimer’s disease (AD) pathophysiology is complex. Decrease in CSF soluble Aβ42/40 and accumulation of amyloid plaques (by amyloid PET) are two distinct biomarkers of amyloid pathology. However, the pathophysiologic process associated with each biomarker is not clear. To this end, we examined CSF protein difference across biological stages defined by biomarkers, with emphasize on early stages of AD where CSF and amyloid PET evaluations are discordant.Method392 nondemented participants from the Alzheimer’s Disease Neuroimaging Initiative (ADNI) were biologically defined base

APA, Harvard, Vancouver, ISO, and other styles

28

Rhodius‐ Meester, Hanneke F. M., Ingrid S. van Maurik, Lyduine E. Collij, et al. "Computerized decision support is an effective approach to select memory clinic patients for amyloid‐PET." Alzheimer's & Dementia 19, S17 (2023). http://dx.doi.org/10.1002/alz.074593.

Full text

Abstract:

AbstractBackgroundThe use of amyloid‐PET in daily clinical practice is upcoming. Yet, ttranslation of the appropriate use criteria (AUC) to clinical practice is challenging, hampering successful implementation of amyloid‐PET. Tools that guide selecting patients for whom amyloid‐PET has most clinical utility are needed. Therefore, we developed and evaluated a computerized decision support approach to select patients for amyloid‐PET testing.MethodWe included 286 subjects (136 controls, 116 Alzheimer’s disease (AD) dementia, 26 frontotemporal lobe dementia (FTD), and 8 vascular dementia (VaD) fro

APA, Harvard, Vancouver, ISO, and other styles

29

Altomare, Daniele, Camilla Caprioglio, Frédéric Assal, et al. "Diagnostic value of amyloid-PET and tau-PET: a head-to-head comparison." European Journal of Nuclear Medicine and Molecular Imaging, February 27, 2021. http://dx.doi.org/10.1007/s00259-021-05246-x.

Full text

Abstract:

Abstract Purpose Assess the individual and combined diagnostic value of amyloid-PET and tau-PET in a memory clinic population. Methods Clinical reports of 136 patients were randomly assigned to two diagnostic pathways: AMY-TAU, amyloid-PET is presented before tau-PET; and TAU-AMY, tau-PET is presented before amyloid-PET. Two neurologists independently assessed all reports with a balanced randomized design, and expressed etiological diagnosis and diagnostic confidence (50–100%) three times: (i) at baseline based on the routine diagnostic workup, (ii) after the first exam (amyloid-PET for the AM

APA, Harvard, Vancouver, ISO, and other styles

30

Daniele, Altomare, Caprioglio Camilla, Assal Frédéric, et al. "Diagnostic value of amyloid-PET and tau-PET: a head-to-head comparison." Eur J Nucl Med Mol Imaging, February 27, 2021. https://doi.org/10.1007/s00259-021-05246-x.

Full text

Abstract:

<strong>Abstract:</strong> Purpose: Assess the individual and combined diagnostic value of amyloid-PET and tau-PET in a memory clinic population. Methods: Clinical reports of 136 patients were randomly assigned to two diagnostic pathways: AMY-TAU, amyloid-PET is presented before tau-PET; and TAU-AMY, tau-PET is presented before amyloid-PET. Two neurologists independently assessed all reports with a balanced randomized design, and expressed etiological diagnosis and diagnostic confidence (50-100%) three times: (i) at baseline based on the routine diagnostic workup, (ii) after the firs

APA, Harvard, Vancouver, ISO, and other styles

31

Reimand, Juhan, Arno de Wilde, Charlotte E. Teunissen та ін. "PET and CSF amyloid-β status are differently predicted by patient features: information from discordant cases". Alzheimer's Research & Therapy 11, № 1 (2019). http://dx.doi.org/10.1186/s13195-019-0561-5.

Full text

Abstract:

Abstract Background Amyloid-β PET and CSF Aβ42 yield discordant results in 10–20% of memory clinic patients, possibly providing unique information. Although the predictive power of demographic, clinical, genetic, and imaging features for amyloid positivity has previously been investigated, it is unknown whether these features differentially predict amyloid-β status based on PET or CSF or whether this differs by disease stage. Methods We included 768 patients (subjective cognitive decline (SCD, n = 194), mild cognitive impairment (MCI, n = 127), dementia (AD and non-AD, n = 447) with amyloid-β

APA, Harvard, Vancouver, ISO, and other styles

32

Sala, Arianna, Agneta Nordberg та Elena Rodriguez-Vieitez. "Longitudinal pathways of cerebrospinal fluid and positron emission tomography biomarkers of amyloid-β positivity". Molecular Psychiatry, 11 грудня 2020. http://dx.doi.org/10.1038/s41380-020-00950-w.

Full text

Abstract:

AbstractMismatch between CSF and PET amyloid-β biomarkers occurs in up to ≈20% of preclinical/prodromal Alzheimer’s disease individuals. Factors underlying mismatching results remain unclear. In this study we hypothesized that CSF/PET discordance provides unique biological/clinical information. To test this hypothesis, we investigated non-demented and demented participants with CSF amyloid-β42 and [18F]Florbetapir PET assessments at baseline (n = 867) and at 2-year follow-up (n = 289). Longitudinal trajectories of amyloid-β positivity were tracked simultaneously for CSF and PET biomarkers. In

APA, Harvard, Vancouver, ISO, and other styles

33

Theodorou, Aikaterini, Konstantinos Melanis, Athanasia Athanasaki, et al. "Cerebral amyloid angiopathy and amyloid load distribution detected on amyloid–positron emission tomography: A systematic review and meta-analysis." European Stroke Journal, June 24, 2025. https://doi.org/10.1177/23969873251349657.

Full text

Abstract:

Introduction: There are limited data regarding the amyloid positron emission tomography (PET) imaging among patients with Cerebral Amyloid Angiopathy (CAA). We sought to assess the amyloid load distribution detected on amyloid-PET among CAA patients compared to patients with Alzheimer’s Disease (AD), patients with hypertension (HTN) related hemorrhage (ICH) and healthy controls (HC). Patients and methods: A systematic review and meta-analysis of published studies with available data on global and regional amyloid-PET uptake was conducted. Comparisons with respect to amyloid load distribution w

APA, Harvard, Vancouver, ISO, and other styles

34

Ennis, Gilda E., Derek Norton, Rebecca E. Langhough, et al. "The performance of plasma p‐tau217 in Black middle‐aged and older adults." Alzheimer's & Dementia 21, no. 5 (2025). https://doi.org/10.1002/alz.70288.

Full text

Abstract:

AbstractINTRODUCTIONMedical conditions prevalent in Black adults within the United States have been associated with plasma tau phosphorylated at threonine 217 (p‐tau217); however, insufficient p‐tau217 research has been conducted with Black adults.METHODSParticipants included n = 233 predominantly cognitively unimpaired adults enrolled in the African Americans Fighting Alzheimer's in Midlife study. Subsamples had creatinine (n = 137) and positron emission tomography (PET; amyloid‐PET = 65 [amyloid‐PET‐positive = 16/65]; tau‐PET = 70). We tested whether p‐tau217 (ALZPath, Inc.) varied by medica

APA, Harvard, Vancouver, ISO, and other styles

35

Cullen, Nicholas C., Shorena Janelidze, Erik Stomrud та ін. "Plasma amyloid-β42/40 and APOE for amyloid PET pre-screening in secondary prevention trials of Alzheimer’s disease". Brain Communications, 24 січня 2023. http://dx.doi.org/10.1093/braincomms/fcad015.

Full text

Abstract:

Abstract The extent to which newly developed blood-based biomarkers could reduce screening costs in secondary prevention trials of Alzheimer’s disease is mostly unexplored. We collected plasma amyloid-β42/40, APOE ε4 status, and amyloid PET at baseline in 181 cognitively unimpaired participants (age of 72.9 [5.3] years; 61.9% female; education of 11.9 [3.4] years) from the Swedish BioFINDER-1 study. We tested whether a model predicting amyloid PET status from plasma amyloid-β42/40, APOE status, and age (combined) reduced cost of recruiting amyloid PET+ cognitively unimpaired participants into

APA, Harvard, Vancouver, ISO, and other styles

36

Lin, Szu-Ying, Kun-Ju Lin, Po-Chen Lin, et al. "Plasma amyloid assay as a pre-screening tool for amyloid positron emission tomography imaging in early stage Alzheimer’s disease." Alzheimer's Research & Therapy 11, no. 1 (2019). http://dx.doi.org/10.1186/s13195-019-0566-0.

Full text

Abstract:

Abstract Introduction Due to the high cost and high failure rate of ascertaining amyloid positron emission tomography positivity (PET+) in patients with earlier stage Alzheimer’s disease (AD), an effective pre-screening tool for amyloid PET scans is needed. Methods Patients with mild cognitive impairment (n = 33, 24.2% PET+, 42% females, age 74.4 ± 7.5, MMSE 26.8 ± 1.9) and mild dementia (n = 19, 63.6% PET+, 36.3% females, age 73.0 ± 9.3, MMSE 22.6 ± 2.0) were recruited. Amyloid PET imaging, Apolipoprotein E (APOE) genotyping, and plasma amyloid β (Aβ)1–40, Aβ1–42, and total tau protein quanti

APA, Harvard, Vancouver, ISO, and other styles

37

Pletnikova, Alexandra, Hamid R. Okhravi, Nimra Jamil, Mackenzie Kirby, Constantine G. Lyketsos, and Esther S. Oh. "Utility of amyloid PET Imaging in a Memory Clinic." Alzheimer Disease & Associated Disorders, August 11, 2023. http://dx.doi.org/10.1097/wad.0000000000000575.

Full text

Abstract:

There is greater interest in amyloid biomarker for the diagnosis of Alzheimer disease (AD) with the recent Food and Drug Administration approval of amyloid-targeted therapy. The goal of this study was to assess the clinical utility of amyloid positron emission tomography (PET) in clinically ambiguous cases of cognitive impairment by examining outcomes of patients enrolled in the Imaging Dementia-Evidence of Amyloid Scanning study at 2 academic institutions. Of the 112 patients in the study, 66.1% (n=74) of patients had a positive amyloid PET scan, and 33.96% (n=38) had a negative amyloid PET s

APA, Harvard, Vancouver, ISO, and other styles

38

Lojo-Ramírez, Jose Antonio, Miriam Guerra-Gómez, Alba Marta Marín-Cabañas, et al. "Correlation Between Amyloid PET Imaging and Discordant Cerebrospinal Fluid Biomarkers Results in Patients with Suspected Alzheimer’s Disease." Journal of Alzheimer's Disease, December 19, 2023, 1–12. http://dx.doi.org/10.3233/jad-230744.

Full text

Abstract:

Background: Although the concordance between cerebrospinal fluid (CSF) Alzheimer’s disease (AD) biomarkers and amyloid-PET findings is well known, there are no data regarding the concordance of amyloid-PET with inconclusive CSF values of amyloid-β (Aβ)1 - 42 and p-tau for the diagnosis of AD. Objective: To investigate the relationship between the amyloid-PET results with discordant AD biomarkers values in CSF (Aβ 1 - 42+/p-tau–or Aβ 1 - 42–/p-tau+). Methods: An observational retrospective study, including 62 patients with mild cognitive impairment (32/62) or dementia (30/62), suspicious of AD

APA, Harvard, Vancouver, ISO, and other styles

39

de Bruin, Hannah, Colin Groot, Suzie Kamps та ін. "Amyloid‐β and tau accumulation in traumatic brain injury: A study of Vietnam war veterans". Alzheimer's & Dementia 19, S16 (2023). http://dx.doi.org/10.1002/alz.079706.

Full text

Abstract:

AbstractBackgroundTraumatic brain injury (TBI) is widely viewed as a risk factor for dementia. Since amyloid‐β and tau pathology have been reported in up to a third of individuals with TBI – even after a single TBI event – their accumulation could be a potential mechanism underlying this association. The aim of this study was to examine the relationship between TBI and amyloid‐β and tau pathology more closely and to assess whether the association between amyloid‐β and tau is influenced by TBI status.MethodA total of 102 Vietnam war veterans (79% normal cognition, 21% mild cognitive impairment;

APA, Harvard, Vancouver, ISO, and other styles

40

Huang, Kuo‐Lun, Ing‐Tsung Hsiao, Chi‐Wei Huang, et al. "The Taiwan‐ADNI workflow toward integrating plasma p‐tau217 into prediction models for the risk of Alzheimer's disease and tau burden." Alzheimer's & Dementia, January 8, 2025. https://doi.org/10.1002/alz.14297.

Full text

Abstract:

AbstractINTRODUCTIONWe integrated plasma biomarkers from the Taiwan Alzheimer's Disease Neuroimaging Initiative and propose a workflow to identify individuals showing amyloid‐positive positron emission tomography (PET) with low/intermediate tau burden based on [18F]Florzolotau PET‐based quantification.METHODSWe assessed 361 participants across the Alzheimer's disease (AD) and non‐AD continuum and measured plasma phosphorylated tau (p‐tau)217, p‐tau181, amyloid beta (Aβ)42/40 ratio, neurofilament light chain, and glial fibrillary acidic protein levels at two medical centers. We evaluated the di

APA, Harvard, Vancouver, ISO, and other styles

41

Pyun, Jung-Min, Young Ho Park, Young Chul Youn та ін. "Characteristics of discordance between amyloid positron emission tomography and plasma amyloid-β 42/40 positivity". Translational Psychiatry 14, № 1 (2024). http://dx.doi.org/10.1038/s41398-024-02766-6.

Full text

Abstract:

AbstractVarious plasma biomarkers for amyloid-β (Aβ) have shown high predictability of amyloid PET positivity. However, the characteristics of discordance between amyloid PET and plasma Aβ42/40 positivity are poorly understood. Thorough interpretation of discordant cases is vital as Aβ plasma biomarker is imminent to integrate into clinical guidelines. We aimed to determine the characteristics of discordant groups between amyloid PET and plasma Aβ42/40 positivity, and inter-assays variability depending on plasma assays. We compared tau burden measured by PET, brain volume assessed by MRI, cros

APA, Harvard, Vancouver, ISO, and other styles

42

Abu Raya, Maison, Ehud Zeltzer, Ganna Blazhenets, et al. "Sex differences in amyloid PET in a large, real‐world sample from the Imaging Dementia–Evidence for Amyloid Scanning (IDEAS) Study." Alzheimer's & Dementia 21, no. 5 (2025). https://doi.org/10.1002/alz.70304.

Full text

Abstract:

AbstractINTRODUCTIONWe examined sex effects on amyloid positron emission tomography (PET) in a large cohort of patients evaluated for cognitive complaints in a “real‐world” specialty setting.METHODSWe analyzed 10,361 amyloid PET scans (51% females) from the Imaging Dementia–Evidence for Amyloid Scanning Study. Amyloid positivity was defined by either local visual read or central PET processing and quantification (≥ 24.4 Centiloids). Sex differences were examined using multilinear regression and logistic regression adjusted for age, comorbidities, and other demographic and clinical covariates.R

APA, Harvard, Vancouver, ISO, and other styles

43

Levin, Fedor, Irina Jelistratova, Tobey J. Betthauser, et al. "In vivo staging of regional amyloid progression in healthy middle-aged to older people at risk of Alzheimer’s disease." Alzheimer's Research & Therapy 13, no. 1 (2021). http://dx.doi.org/10.1186/s13195-021-00918-0.

Full text

Abstract:

Abstract Background We investigated regional amyloid staging characteristics in 11C-PiB-PET data from middle-aged to older participants at elevated risk for AD enrolled in the Wisconsin Registry for Alzheimer’s Prevention. Methods We analyzed partial volume effect-corrected 11C-PiB-PET distribution volume ratio maps from 220 participants (mean age = 61.4 years, range 46.9–76.8 years). Regional amyloid positivity was established using region-specific thresholds. We used four stages from the frequency-based staging of amyloid positivity to characterize individual amyloid deposition. Longitudinal

APA, Harvard, Vancouver, ISO, and other styles

44

La Joie, Renaud, Nidhi Mundada, Leonardo Iaccarino, et al. "Amyloid‐PET, tau‐PET, and their association in sporadic early‐onset Alzheimer’s Disease: Cross‐sectional and longitudinal data from the LEADS study." Alzheimer's & Dementia 19, S24 (2023). http://dx.doi.org/10.1002/alz.078003.

Full text

Abstract:

AbstractBackgroundWe aimed to describe amyloid‐ and tau‐PET in patients with sporadic Early Onset AD (sEOAD) from the Longitudinal Early‐onset Alzheimer’s Disease Study. We focused on amyloid‐tau relationships and on the association between i) age, sex, and ii) cross‐sectional and longitudinal PET measures.MethodsIn December 2022, we selected patients who fulfilled the following criteria: 1) clinical diagnosis of MCI or mild dementia, 2) available amyloid‐PET (18F‐florbetaben), tau‐PET (18F‐fortaucipir), and structural MRI, 3) positive amyloid‐PET based on a process including visual read and q

APA, Harvard, Vancouver, ISO, and other styles

45

Nikolova, Jennifer, Bryan Woodruff, and Oana Dumitrascu. "Abstract WP61: Automated Retinal Vascular Fractal Analysis Can Screen Presymptomatic Alzheimer’s Disease." Stroke 56, Suppl_1 (2025). https://doi.org/10.1161/str.56.suppl_1.wp61.

Full text

Abstract:

Background: Retinal vasculopathy had been reported across the continuum of neurodegeneration. Retinal color fundus photography coupled with automated retinal vascular analysis offers potential to non-invazively screen for Alzheimer’s disease (AD) neurodegeneration. Amyloid positron emission tomography (PET) and apolipoprotein 4 (APOE4) carrier status are known biomarkers of AD risk. Herein, we examined the relationship between retinal vascular fractal dimensions in non-mydriatic color fundus photographs, amyloid-PET burden and APOE4 carrier status in a cohort of cognitively intact individuals.

APA, Harvard, Vancouver, ISO, and other styles

46

Ramanan, Vijay K., Jonathan Graff‐Radford, Joshua A. Bornhorst, et al. "Amyloid Biomarker Discordance in Patients Evaluated for Anti‐Amyloid Therapy." Alzheimer's & Dementia 20, S8 (2024). https://doi.org/10.1002/alz.095777.

Full text

Abstract:

AbstractBackgroundEvidence for abnormal amyloid‐β (Aβ) plaque accumulation is necessary prior to initiating anti‐amyloid therapy in early symptomatic Alzheimer’s disease (AD). While the clinical trials for lecanemab and related drugs utilized positron emission tomography (PET) to demonstrate brain amyloidosis, current appropriate use recommendations for clinical practice consider PET or cerebrospinal fluid (CSF) biomarkers as satisfactory for this purpose. Here, we present four clinical cases where CSF biomarker results were discordant from amyloid PET, with the potential to result in erroneou

APA, Harvard, Vancouver, ISO, and other styles

47

McCarter, Stuart, Timothy G. Lesnick, Val Lowe та ін. "Cerebral Amyloid Angiopathy Pathology and Its Association With Amyloid-β PET Signal". Neurology, 9 вересня 2021, 10.1212/WNL.0000000000012770. http://dx.doi.org/10.1212/wnl.0000000000012770.

Full text

Abstract:

Objective:To determine the contribution of cerebral amyloid angiopathy (CAA) to Pittsburgh compound B (PiB)-PET tracer retention.Methods:Participants from the Mayo Clinic Study of Aging and Mayo Clinic Alzheimer’s Disease Research Center with antemortem PiB-PET imaging for amyloid beta (Aβ) and later underwent autopsy were included in this study. Pathologic regional leptomeningeal, parenchymal, capillary CAA, and Aβ plaque burden were calculated from one hemisphere. Regional lobar amyloid SUVr on PET was calculated from the same hemisphere sampled at autopsy. Single- and multiple-predictor lin

APA, Harvard, Vancouver, ISO, and other styles

48

Senda, M., K. Ishii, K. Ito, et al. "A Japanese Multicenter Study on PET and Other Biomarkers for Subjects with Potential Preclinical and Prodromal Alzheimer’s Disease." Journal Of Prevention of Alzheimer's Disease, 2021, 1–8. http://dx.doi.org/10.14283/jpad.2021.37.

Full text

Abstract:

BACKGROUND: PET (positron emission tomography) and CSF (cerebrospinal fluid) provide the “ATN” (Amyloid, Tau, Neurodegeneration) classification and play an essential role in early and differential diagnosis of Alzheimer’s disease (AD). OBJECTIVE: Biomarkers were evaluated in a Japanese multicenter study on cognitively unimpaired subjects (CU) and early (E) and late (L) mild cognitive impairment (MCI) patients. MEASUREMENTS: A total of 38 (26 CU, 7 EMCI, 5 LMCI) subjects with the age of 65-84 were enrolled. Amyloid-PET and FDG-PET as well as structural MRI were acquired on all of them, with an

APA, Harvard, Vancouver, ISO, and other styles

49

Rabinovici, Gil D., David S. Knopman, Javier Arbizu, et al. "Updated appropriate use criteria for amyloid and tau PET: A report from the Alzheimer's Association and Society for Nuclear Medicine and Molecular Imaging Workgroup." Alzheimer's & Dementia, January 8, 2025. https://doi.org/10.1002/alz.14338.

Full text

Abstract:

AbstractINTRODUCTIONThe Alzheimer's Association and the Society of Nuclear Medicine and Molecular Imaging convened a multidisciplinary workgroup to update appropriate use criteria (AUC) for amyloid positron emission tomography (PET) and to develop AUC for tau PET.METHODSThe workgroup identified key research questions that guided a systematic literature review on clinical amyloid/tau PET. Building on this review, the workgroup developed 17 clinical scenarios in which amyloid or tau PET may be considered. A modified Delphi approach was used to rate each scenario by consensus as “rarely appropria

APA, Harvard, Vancouver, ISO, and other styles

50

Guillén, Núria, José Contador, Mariateresa Buongiorno, et al. "Agreement of cerebrospinal fluid biomarkers and amyloid-PET in a multicenter study." European Archives of Psychiatry and Clinical Neuroscience, October 28, 2023. http://dx.doi.org/10.1007/s00406-023-01701-y.

Full text

Abstract:

AbstractCore Alzheimer’s disease (AD) cerebrospinal fluid (CSF) biomarkers have shown incomplete agreement with amyloid-positron emission tomography (PET). Our goal was to analyze the agreement between AD CSF biomarkers and amyloid-PET in a multicenter study. Retrospective multicenter study (5 centers). Participants who underwent both CSF biomarkers and amyloid-PET scan within 18 months were included. Clinical diagnoses were made according to latest diagnostic criteria by the attending clinicians. CSF Amyloid Beta1-42 (Aβ1-42, A), phosphorliated tau 181 (pTau181, T) and total tau (tTau, N) bio

APA, Harvard, Vancouver, ISO, and other styles

We offer discounts on all premium plans for authors whose works are included in thematic literature selections. Contact us to get a unique promo code!